Scroll Top

The Next Wave of Personalized Medicine

Discover how Data and AI is Transforming Personalized/Precision Medicine, October 11, 2018

Special guest, Harry Glorikian, General Partner, New Ventures Funds, and author of the top-selling book, MoneyBall Medicine: Thriving in the New Data- Driven Healthcare Market, will be giving the keynote kicking off the conference.

The talk will focus on precision medicine that is personalized to the characteristics of each patient and growing use of AI for drug discovery, clinical trial design and to help diagnose condition and recommend treatment options. Advances in genetics, and the growing availability of health data, present an opportunity to make precise personalized patient care a clinical reality. AI based predictive modeling of biological processes and drugs becomes significantly more sophisticated and widespread. AI will identify patients to enroll in clinical trials based on factors such as genetic information to target specific populations, thereby enabling trials that are smaller, shorter, less expensive, and more powerful. Trials are monitored in real time to rapidly identify safety or operational issues requiring action, resulting in cost savings.


About Harry Glorikian

Harry Glorikian is an influential global business expert with more than three decades of experience building successful ventures in North America, Europe, Asia and the rest of the world. Harry is well known for achievements in life sciences, healthcare, diagnostics, healthcare IT and the convergence of these areas. He is a sought-after speaker, frequently quoted in the media, and regularly asked to assess, influence, and be part of innovative concepts and trends.

He is currently a General Partner at New Ventures Funds (NV). Before joining NV Funds, he served as an Entrepreneur In Residence to GE Ventures – New Business Creation Group. He currently serves on the board of GeneNews Ltd. He also serves on the advisory board of Evidation Health (a digital health startup launched with support from GE Ventures), and several other companies. He is also a co-founder and an advisory board member of DrawBridge Health (a revolutionary diagnostics startup launched with support from GE Ventures).

Harry holds an MBA from Boston University and a bachelor’s degree from San Francisco State University. Harry has addressed the NIH, Molecular Medicine Tri-Conference, World Theranostics Congress and other audiences, worldwide. He has authored numerous articles, appeared on CBS Evening News and been quoted regularly by Dow Jones, The Boston Globe, Los Angeles Times, London Independent, Medical Device Daily, Science Magazine, Genetic Engineering News and many others.